Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture
Bone Fracture, Fresh Fracture
About this trial
This is an interventional treatment trial for Bone Fracture focused on measuring Low-Intensity Ultrasound, Drug Delivery, Sonophoresis, Transdermal Drug Delivery, Non-Steroidal Anti-Inflammatory Drugs, Sustained Acoustic Medication, Low-Intensity Continuous Ultrasound
Eligibility Criteria
Inclusion Criteria: Have physician-diagnosed bone fracture Are between 18-80 years of age Report a pain score between 3-7 (range: 0-10) prior to enrolment Report that pain from fracture negatively affects quality of life Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study Are deemed appropriate by their physician or by the study site physician to participate. Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device. Not use or initiate opioid and/or non-opioid analgesic medications. Be willing to discontinue any other interventional treatment modalities on the affected area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound). Exclusion Criteria: Cannot successfully demonstrate the ability to put on and take off the device. Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions. Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening. Is pregnant. Is a prisoner. Is non-ambulatory (unable to walk). Has a pacemaker. Has a malignancy in the treatment area. Has an active infection, open sores, or wounds in the treatment area. Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia. Has a known neuropathy (disease of the brain or spinal nerves). Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage). Are currently taking steroids.
Sites / Locations
- ZetrOZ Systems LLCRecruiting
- National Sports Medicine InstituteRecruiting
Arms of the Study
Arm 1
Experimental
SAM Ultrasound Device and Diclofenac Patch
Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 12 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm^2 intensity.